PRMT5 as a druggable target for glioblastoma therapy

BACKGROUND: In spite of standard multimodal therapy consisting of surgical resection followed by radiation and concurrent chemotherapy, prognosis for glioblastoma (GBM) patients remains poor. The identification of both differentiated and undifferentiated “stem cell like” populations in the tumor hig...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Autores principales: Banasavadi-Siddegowda, Yeshavanth Kumar, Welker, Alessandra M, An, Min, Yang, Xiaozhi, Zhou, Wei, Shi, Guqin, Imitola, Jaime, Li, Chenglong, Hsu, Sigmund, Wang, Jiang, Phelps, Mitch, Zhang, Jianying, Beattie, Christine E, Baiocchi, Robert, Kaur, Balveen
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2018
Materias:
Basic and Translational Investigations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5961180/
https://ncbi.nlm.nih.gov/pubmed/29106602
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox206
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares